About AcuCort

Our vision

AcuCort’s vision is that ISICORT® will be globally commercialized, be well integrated and used in the treatment/risk management of acute and severe allergic reactions and croup in children, and see wide use against chemotherapy-induced nausea and vomiting (CINV.)

Business idea

AcuCort shall develop and commercialize ISICORT® supported by a global network of licensees and/or distributors. AcuCort intends also to identify, develop and commercialize complementary smart products with short time to marketing approval based on existing substances.

About AcuCort

AcuCort AB was founded in 2006 as a subsidiary of DuoCort AB. 2011 marked a new beginning for AcuCort and its development project, as the life science company Partners för Utvecklingsinvesteringar inom Life Sciences, P.U.L.S. AB acquired the company from DuoCort AB. From that time onward, AcuCort was managed as a part of the PULS group (now known as AQILION AB) until the successful IPO (Initial Public Offering) in April of 2017 when AcuCort was listed in Sweden. AQILION AB has remained the principal owner of AcuCort.

AcuCort develops and commercializes ISICORT®, a fast-dissolving oral film containing the glucocorticoid dexamethasone. In the development of ISICORT®, the advantages of the frequently used and well-documented substance dexamethasone and the fast-dissolving oral film have been combined for rapid access and relief in acute situations.

The new innovative drug ISICORT® is approved in Sweden for the treatment of acute and severe allergic reactions, croup in children, chemotherapy-induced nausea and vomiting (CINV) as well as Covid-19 patients who need supplemental oxygen treatment. The registration process in Denmark, Finland, Iceland and Norway regarding ISICORT® is currently ongoing via a so-called reciprocal procedure, Mutual Recognition Process (MRP).


AcuCort AB’s share is listed on Spotlight Stock Market, in Sweden, since April 24, 2017, under the ticker (ACUC) and is traded through banks and stockbrokers.

In the spring of 2017, AcuCort carried out a successful emission amounting to MSEK 14 after financing costs. The issue was subscribed to by more than 900 investors. The principal owner, Partners för Utvecklingsinvesteringar inom Life Sciences, P.U.L.S. AB (now AQILION AB) also took part in the issue.

In the autumn of 2018, AcuCort carried out a successful rights issue and an oversubscription of just under MSEK 11 after financing costs.

The capital raised in the issues in 2017 and 2018 has mainly used for finalization of product development, scaling up of production, and production of GMP grade batches. As well as, one pivotal bioequivalence study in the EU and two in the US (one with fasting participants and one with non-fasting participants) and the compilation of an national application for market approval in Sweden. The company sent in an application regarding national market approval of ISICORT® in Sweden to the Swedish Medical Products Agency (MPA) in September of 2019. On October 7, 2020, AcuCort received the market approval from the Swedish Medical Products Agency for the drug ISICORT®. The aim is that, as soon as possible after the Swedish approval, extend the application to several EU countries via the so-called reciprocal procedure, Mutual Recognition Process (MRP).

In the autumn of 2019, AcuCort carried out a new share issue with preferential rights for the shareholders. The issue was subscribed to 101.7 percent and AcuCort received approximately MSEK 41.2 before issue costs. The issue proceeds will finance the company’s commercialization of ISICORT®.

During the fourth quarter of 2021, a directed new issue of SEK 5 million was carried out, as well as a rights issue of SEK 26 million. The capital will primarily finance the forthcoming registration of ISICORT® in the USA and commercialization in priority markets.

Read more about the development of the project on the page Research & Development.

Intellectual property

AcuCort’s ISICORT® is protected by two patent families (approved patents and patent applications) and considerable technical know-how concerning dexamethasone and oral films.

AcuCort’s network and principal owner

AcuCort is a member company of SwedenBIO, the national non-profit association for the life science industry in Sweden. Learn more at www.swedenbio.se.

The principal owner AQILION AB is a Swedish privately held biotechnology company focused on developing new innovative treatments for diseases caused by chronic inflammation and dysfunctional immunological reactions such as autoimmunity, www.aqilion.com.